FDA Pulls Plug on Two Drugs at Companies' Own Request
Published Date: 5/30/2025
Notice
Summary
The FDA is officially pulling the plug on two drug approvals from Meda AB and B. Braun Medical, Inc. because the companies told the FDA they stopped selling these drugs. This means these drugs won’t be available anymore, but no one will lose money or face surprises since the companies asked for this. If you used these drugs, it’s time to check with your doctor for alternatives!
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
Two Drugs Removed From Market
The FDA is withdrawing approval of two new drug applications from Meda AB and B. Braun Medical, Inc. because those companies told the FDA they stopped marketing the products and asked for withdrawal. The drugs will no longer be available, and the FDA says no one will lose money or face surprises because the companies requested this; if you used these drugs, check with your doctor about alternatives.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-09780, Agency Information Collection Proposed Extension
The Energy Information Administration (EIA) wants to keep collecting important info on natural gas liquids and oil and gas reserves for three more years, with some updates to the forms. They’re also keeping one survey paused for now. If you’re involved in the energy industry, this affects you, and the EIA is asking for your thoughts before moving forward—so don’t miss the chance to weigh in!
Next: 2025-09782, Polypropylene Corrugated Boxes From the People's Republic of China: Postponement of Preliminary Determination in the Countervailing Duty Investigation
The U.S. is investigating if Chinese polypropylene corrugated boxes get unfair government help. The first big decision on this is delayed from June 11 to a later date to give everyone more time to cooperate and sort out tricky details. This affects importers, manufacturers, and anyone watching trade rules, with possible impacts on duties and prices down the line.